ESMO 2016: Q&A on Friday's press briefs

ESMO 2016: Q&A on Friday's press briefs

VJOncology

3 years
568 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
In this press brief Q&A from ESMO 2016, Solange Peters, MD, PhD of Lausanne University Hospital, Lausanne, Switzerland, Lidija Kandolf-Sekulovic, MD, PhD of the Military Medical Academy, Belgrade, Serbia, Josep Tabernero, MD, PhD of Vall d'Hebron University Hospital, Barcelona, Spain, Andrés Cervantes, MD, PhD of University of Valencia, Valencia, Spain, Ulrik Lassen, MD, PhD of Copenhagen University Hospital, Copenhagen, Denmark and Fortunato Ciardiello, MD, PhD of Second University of Naples, Naples, Italy answer questions from the audience on the press briefs from Friday.
Up Next Autoplay
Loss of SETD2 is associated with dysregulation of protein translation in clear cell renal cell carcinoma
Loss of SETD2 is associated with dysregulation of protein translation in clear cell renal cell carcinoma
Category: Kidney Cancer
2 Views
kidneycancer 1 day
Immune Correlates and Prognostic Significance of CD73 Expression in Renal Cell Carcinoma
Immune Correlates and Prognostic Significance of CD73 Expression in Renal Cell Carcinoma
Category: Kidney Cancer
5 Views
kidneycancer 1 day
Using Epigenetic Therapy to Enhance Immunotherapy Response in RCC
Using Epigenetic Therapy to Enhance Immunotherapy Response in RCC
Category: Kidney Cancer
4 Views
kidneycancer 1 day
Radiation to Prime the Immune System
Radiation to Prime the Immune System
Category: Kidney Cancer
8 Views
kidneycancer 1 day
Therapeutic targeting of the extracellular matrix in kidney cancer
Therapeutic targeting of the extracellular matrix in kidney cancer
Category: Kidney Cancer
2 Views
kidneycancer 1 day
Innate Cytokines and Myeloid Cells
Innate Cytokines and Myeloid Cells
Category: Kidney Cancer
1 Views
kidneycancer 1 day
DNA Demethylation promotes ERV expression and activation of immune signaling in renal cell cancer cells
DNA Demethylation promotes ERV expression and activation of immune signaling in renal cell cancer cells
Category: Kidney Cancer
0 Views
kidneycancer 1 day
The T-cell response to Kidney Cancer
The T-cell response to Kidney Cancer
Category: Kidney Cancer
1 Views
kidneycancer 1 day
Discovery of new IO Targets Leveraging CRISPR
Discovery of new IO Targets Leveraging CRISPR
Category: Kidney Cancer
1 Views
kidneycancer 1 day
Patient-reported ECOG performance status (PS) is lower than oncologist-reported PS and is associated with worse psychosocial outcomes
Patient-reported ECOG performance status (PS) is lower than oncologist-reported PS and is associated with worse psychosocial outcomes
Category: Kidney Cancer
2 Views
kidneycancer 1 day